A New Order in APAC Biosimilar Market: From Manufacturing Powerhouses to Value-Driven Innovators

As the global healthcare industry confronts mounting cost pressures, the Asia-Pacific (APAC) region has emerged as one of the fastest-growing arenas for biosimilars. Beneath this expansion lies a seismic shift: the nature of competition has evolved from cost and scale dominance to a more complex battle involving clinical trust, regulatory agility, and high-value transformation.

In this in-depth feature, we explore how APAC biosimilar powerhouses—South Korea’s Celltrion and Samsung Bioepis, alongside India’s Biocon and Dr. Reddy’s—are redefining the future of biosimilars. Amid diverging market needs, maturing healthcare systems, and intensifying price compression, these companies are deploying forward-looking strategies to secure their foothold in the next era of global biopharmaceutical competition.

The Rise of Manufacturing Titans: How South Korea and India Took the Lead

Once viewed as peripheral manufacturing hubs, South Korea and India have become central players in the global biosimilar race. Their leading companies have transitioned from cost-based suppliers to globally recognized biopharma contenders. South Korea’s Celltrion and Samsung Bioepis have invested heavily in production capacity while accelerating their global footprint. 

Celltrion, for example, has expanded its biosimilar portfolio to target autoimmune and orthopedic indications while increasing its visibility at international biopharma conferences to forge partnerships and boost brand recognition. Samsung Bioepis, leveraging strategic alliances with global firms like Biogen, has broken into high-barrier markets such as the U.S. and Europe.

Meanwhile, Indian giants Biocon and Dr. Reddy’s are solidifying India’s status as the “pharmacy of the world.” Biocon has benefited from favorable government policies and strong intellectual property infrastructure. Its subsidiary, CuraTeQ Biologics, achieved GMP certification from the European Medicines Agency (EMA), allowing seamless entry into highly regulated markets.

Dr. Reddy’s, on the other hand, has adopted a highly diversified market strategy, expanding into Central Asia, Southeast Asia, and Latin America, while partnering with local distributors to penetrate new territories quickly. These companies are shifting away from the low-cost label and instead positioning themselves as quality-driven, regulatory-compliant, globally competitive manufacturers.

Beyond Price Wars: Navigating Trust and Market Access Barriers

Despite its explosive growth, the APAC biosimilar market remains complex and uneven. In mature markets like Japan and South Korea, biosimilars still face significant barriers to clinical adoption. While the European average biosimilar penetration exceeds 70%, Japan and South Korea lag behind at only 38.77% and 28.79%, respectively. 

This disparity is rooted in deeply ingrained clinical conservatism and payer hesitancy. In Japan, physicians often demand data exceeding the regulatory minimums before prescribing biosimilars. In South Korea, most patients use biosimilars based on physician recommendation, underscoring the critical role of trust in market penetration.

In these mature markets, companies are pivoting away from pricing strategies and focusing on evidence-based engagement. They are investing in real-world evidence, pharmacoeconomic modeling, and intensive negotiation with reimbursement bodies. Meanwhile, in emerging markets like China and India, the dynamics are reversed. Price and procurement drive competition. 

Success hinges on rapid supply chain deployment, participation in national tenders, and close alignment with government purchasing programs. Companies must not only manufacture efficiently but also navigate the nuances of state-driven pricing schemes and fragmented healthcare access to build defensible scale.

Betting Big on mAbs and Oncology: The Dual Engines of Growth

As the market matures, competition is no longer just about access—it’s about what you’re selling and where. Monoclonal antibodies (mAbs) dominate the biosimilar landscape, accounting for 44.98% of global market share in 2024. 

In APAC, the same trend holds, with biosimilars targeting indications in oncology and autoimmune diseases becoming central to company pipelines. Celltrion and Biocon are at the forefront, developing biosimilars for high-value targets like trastuzumab, rituximab, and adalimumab, while also venturing into next-generation modalities such as bispecific antibodies and fusion proteins.

Entering the market also requires strategic agility. In mature markets, companies must deliver beyond regulatory compliance—offering robust clinical packages, engaging key opinion leaders (KOLs), and securing payer support through comprehensive data. In emerging markets, success hinges on speed, affordability, and broad-based access. 

This demand for segmentation forces companies to design highly localized strategies. Samsung Bioepis exemplifies this approach, using adaptable commercial playbooks to penetrate diverse markets across Europe, North America, and Asia. Product portfolio depth and market-entry flexibility are now essential differentiators in an increasingly competitive landscape.

The Value Transformation: CDMO and ADCs Reshape the Competitive Landscape

With pricing pressure steadily eroding margins, leading APAC biosimilar firms are aggressively diversifying into high-value verticals—most notably CDMO services and antibody-drug conjugates (ADCs). Samsung Bioepis has made headlines with its investment of over KRW 3 trillion (~USD 2.2 billion) to build the world’s largest biologics manufacturing site in Songdo, signaling its transition from product maker to biopharma service provider. 

The CDMO model offers stable, lower-risk cash flow, enabling companies to repurpose their production assets for global clientele while expanding revenue streams beyond biosimilar launches.

On the innovation front, Celltrion and Biocon are investing in ADC development, capitalizing on their existing monoclonal antibody expertise to enter this high-barrier, high-margin space. ADCs are increasingly seen as the next frontier in precision oncology, offering enhanced efficacy through targeted delivery. 

Unlike biosimilars, which suffer from rapid commoditization, ADCs require complex linker-payload technologies and manufacturing capabilities that are difficult to replicate. For APAC players, this pivot is a strategic bet on future market relevance and profitability.

This dual-track transformation—from product manufacturer to service platform and from biosimilar to high-complexity biologics—signals a radical redefinition of what it means to be a successful biopharma company in APAC. 

The winners will not merely be the lowest-cost producers but those that can offer end-to-end value: from development and regulatory support to flexible manufacturing and lifecycle management.

A Decade of Opportunity and Disruption: The APAC Blueprint in Motion

The Asia-Pacific biosimilar market stands at a historic inflection point. The old paradigm of cost and capacity is rapidly giving way to a new model built on trust, evidence, and strategic diversification. The future leaders will not simply be those with the biggest factories, but those capable of integrating clinical insight, regulatory expertise, and global collaboration into a cohesive value proposition.

South Korean and Indian firms are already demonstrating this shift, executing strategies that combine scale, compliance, and innovation. Meanwhile, multinational giants are adapting by forming regional alliances and investing in APAC capabilities to keep pace. From product selection to portfolio strategy, and from market access to platform transformation, every aspect of the biosimilar game is being rewritten.

The coming decade will see a convergence of trends: deeper clinical engagement, intensified value-chain integration, and rising complexity in payer and regulatory landscapes. Those who can navigate this evolving terrain will not only survive—but lead. In the new APAC biosimilar order, competition is no longer about who can manufacture, but who can matter.

Editor’s Synopsis: The New APAC Biopharma Order

The Asian biopharmaceutical industry is undergoing a fundamental transformation, moving far beyond its origins as a high-volume manufacturer of biosimilars. For the past decade, APAC giants—led by South Korea’s Samsung Bioepis and Celltrion, and India’s Biocon—successfully captured global market share by mastering a strategy of “manufacturing victory,” built on producing high-quality, low-cost biosimilars.

This analysis reveals that the old paradigm, defined by competition on cost and scale, is rapidly becoming obsolete. These manufacturing titans now face a severe “trust and margin” squeeze from two directions. In emerging markets like China and India, the field has become a red ocean, defined by ruinous price wars and government-led procurement that compresses margins. Simultaneously, in high-value mature markets like Japan and Korea, they face a significant “trust barrier.” Deep-seated clinical conservatism means physicians overwhelmingly prefer originator brands, forcing biosimilar makers to invest heavily in expensive Real-World Evidence (RWE) studies just to gain adoption—a strategy that fundamentally erodes their low-cost advantage.

In response to this existential challenge—where being “cheap is no longer enough”—these firms are executing a profound “value transformation,” pivoting from mere manufacturers into a new class of indispensable industry leaders. This strategic pivot is unfolding along two distinct high-value tracks.

The first track is a pivot to “Platform as a Service,” exemplified by Samsung. By investing billions (e.g., over $2.2B in its Songdo “super plant”), Samsung is aggressively transitioning into the “TSMC of Biotech“—a high-end Contract Development and Manufacturing Organization (CDMO). This strategy leverages its core manufacturing prowess to generate stable, low-risk, service-based cash flows from a global clientele, moving beyond the volatility of the product market.

The second track is a leap into “Value Innovation,” led by players like Celltrion and Biocon. This strategy involves leveraging biosimilar cash flows to fund high-barrier R&D in novel therapeutics. They are aggressively moving into complex, next-generation modalities, most notably Antibody-Drug Conjugates (ADCs). By developing these “biological missiles,” which are technologically difficult to replicate, they are strategically escaping the commoditization trap and entering the high-margin frontier of precision oncology.

The conclusion is clear: the old era of APAC biotech competition, defined by cost and capacity, is over. The future winners will not be the lowest-cost producers but the firms that successfully complete this transformation. The essence of competition has shifted from a question of “who can manufacture” to the far more critical question of “who can matter” by providing indispensable end-to-end value.

Related posts:

Two South Korean Companies Look to Capture the Biosimilars Market Worth Billions Samsung Biologics Snaps Up Biogen’s Stake in Samsung Bioepis for $2.3 Billion, Assuming Full Control of Biosimilar Venture CDMO Samsung Bio Secures Record $1.24 Billion Biopharma Manufacturing Contract, Raising Total 2024 Deal Value to Over $3.3 Billion Weekly in Asia ｜Nov

Author

Oscar Wu

讓生醫資訊更加流通與透明化。